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■ EDITORIAL ■
Tamoxifen, the first clinically available selective estrogen
receptor modulator, was developed in 1966 and has
been proven to be efficacious in all settings of breast
cancer [1]. However, a series of case reports announced
an association between tamoxifen therapy in women
with breast cancer and the development of endometrial
carcinoma in the mid-to-late 1980s [1]. In the previous
issue of the Taiwanese Journal of Obstetrics and Gynecology
[2], Dr Wu reported a rare case of secretory endome-
trial adenocarcinoma in a 71-year-old woman who
was a victim of stage II breast cancer treated by mas-
tectomy, chemotherapy, and 10-year daily tamoxifen.
Adjuvant therapy with tamoxifen after breast cancer
should be reconsidered because of the many possible
side effects.
Tamoxifen has demonstrated special efficacy in the
treatment and prevention of estrogen receptor (ER)-
positive breast carcinoma [3,4]. Three randomized tri-
als are prospectively evaluating tamoxifen (Nolvadex®;
AstraZeneca, Wilmington, DE, USA) for breast cancer
risk reduction [5–8]. The International Breast Cancer
Intervention Study I (IBIS-I) trial showed a 25% reduc-
tion in the risk of invasive breast cancer with tamoxifen
[9]. A meta-analysis of these studies, of which the
National Surgical Breast and Bowel Project P-1 trial
contributed the largest proportion of entered patients,
identified a significant 42% reduction in relative risk
(RR) of developing breast cancer associated with
tamoxifen use (RR, 0.58; 95% confidence interval, CI,
0.38–0.84) [5]. The absolute risk reduction in these
trials was less than 2 per 100 women given tamoxifen
for 5 years [8]. The absolute risk reduction anticipated
in an individual woman depends on her calculated
breast cancer risk, with women at higher risk having
greater potential benefit [9]. For example, the average
65-year-old woman with no family history has an antic-
ipated risk reduction of 1 per 100, while a 50-year-old
woman with two affected siblings and two prior biop-
sies but no germline mutation has an anticipated risk
reduction of approximately 2.5 per 100. In an overview
of data from 37,000 women with breast cancer from
55 trials of adjuvant therapy, the proportional reduc-
tion in recurrence was 47% after 5 years of treatment
with tamoxifen and the proportional reduction in mor-
tality was 26% after 10 years [10]. The absolute
improvements in 10-year survival were 10.9% in node-
positive and 5.6% in node-negative breast cancer. 
In contrast, women with ER-negative disease had little,
if any, benefit [11,12]. Best results appear to be
achieved after 5 years of treatment; thereafter, the ben-
eficial effects decrease and toxicity increases [13–15],
although the optimal duration of administration is
still under investigation [3]. Nevertheless, tamoxifen-
stimulated breast cancer is well recognized [16] and
provides the rationale for stopping tamoxifen therapy
at 5 years.
About half of the women with advanced ER-positive
breast cancer will have a response to tamoxifen therapy,
whereas only 5% with ER-negative breast cancer will
have a response [4,14]. The reduction in the risk of con-
tralateral breast cancer in adjuvant trials of tamoxifen
led to its inclusion in randomized primary-prevention
trials. Among the 13,388 participants in the breast
cancer prevention trial, there was a 49% reduction in
the risk of invasive breast cancer, but the benefit of
tamoxifen was limited to ER-positive tumors with a
69% reduction [5].
Tamoxifen was also reported to reduce the risk of
fractures, though not significantly. However, it was
associated with increased risks of endometrial cancer,
stroke, pulmonary embolism, deep vein thrombosis, and
cataract, primarily in women 50 years of age or older
[5,17–19]. Tamoxifen increased the risk of stroke (RR,
1.75; 95% CI, 0.98–3.20), deep vein thrombosis (RR,
1.71; 95% CI, 0.85–3.58), and pulmonary emboli 
(RR, 3.19; 95% CI, 1.12–11.15), although only the risk
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of pulmonary embolism reached statistical significance
[5]. The incidence of pulmonary embolism was increased
from 0.31 per 1,000 women per year to 1 per 1,000
women per year. The incidence of endometrial carci-
noma was increased fourfold, but no deaths due to
endometrial carcinoma occurred in the tamoxifen arm.
Endometrial cancer occurred in 3.05 per 1,000 women
per year taking tamoxifen [5]. Bernstein et al examined
the effect of the known risk factors for endometrial
carcinoma (i.e. obesity and previous estrogen use) in
women taking tamoxifen [20]. They found no increase
in endometrial cancer with tamoxifen use in the absence
of these factors. Tamoxifen was also noted to increase
the risk of cataract surgery from 3 per 1,000 to 4.72
per 1,000 per year [5].
No trial has shown improved survival with tamoxifen.
In fact, there were slightly more deaths in the tamoxifen
group of the IBIS-I trial due to an increase in throm-
boembolic events [9]. A recent evidence-based tech-
nology assessment by the American Society of Clinical
Oncology indicated that tamoxifen’s favorable effect
on the risk of breast cancer must be weighed against
its potential side effects in individual women [8]. The
conclusions drawn from the assessment were: (1) for
women with a 5-year projected breast cancer risk
greater than 1.66%, tamoxifen (20 mg/day for 5 years)
may be offered to reduce risk; (2) consideration of
tamoxifen is appropriate for the goal of lowering the
short-term risk of developing breast cancer; (3)
risk/benefit models suggest that the greatest clinical
benefit with least side effects are derived from use of
tamoxifen in younger, premenopausal women who are
less likely to have thromboembolic sequelae and uterine
cancer, in women without a uterus, and in women at
higher breast cancer risk; and (4) data do not as yet
suggest that tamoxifen provides an overall health ben-
efit or increases survival [8].
Therefore, the use of selective estrogen receptor
modulators other than tamoxifen, such as the new-
generation aromatase inhibitors or pure estrogen recep-
tor antagonists, may be a better choice for breast cancer
prevention. Results from the Study of Tamoxifen and
Raloxifene (STAR) trial involving 20,000 women were
released in April 2006, more than a year ahead of
schedule [21]. The findings revealed that raloxifene’s
greatest advantage over tamoxifen appears to be fewer
serious side effects, including uterine cancer, blood
clots, and cataracts [21]. The results of this trial have
prompted the manufacturer of raloxifene, Eli Lilly, to
petition the Food and Drug Administration for permis-
sion to market raloxifene for breast cancer prevention.
Physicians across the United States are now anticipat-
ing an influx of requests from postmenopausal women
for raloxifene [17]. Vastag further pointed out the
vision of raloxifene, suggesting that raloxifene prevails
in the STAR trial and may face an easier road to
acceptance than previous drugs [17]. Only time will
tell whether raloxifene will be the preferred choice.
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